



## City Research Online

### City, University of London Institutional Repository

---

**Citation:** Palma, P., Gudmundsdotter, L., Finocchi, A., Eriksson, L. E., Mora, N., Santilli, V., Aquilani, A., Manno, E. C., Zangari, P., Romiti, M. L., et al (2014). Immunotherapy with an HIV-DNA Vaccine in Children and Adults. *Vaccines*, 2(3), pp. 563-580. doi: 10.3390/vaccines2030563

This is the published version of the paper.

This version of the publication may differ from the final published version.

---

**Permanent repository link:** <https://openaccess.city.ac.uk/id/eprint/6415/>

**Link to published version:** <https://doi.org/10.3390/vaccines2030563>

**Copyright:** City Research Online aims to make research outputs of City, University of London available to a wider audience. Copyright and Moral Rights remain with the author(s) and/or copyright holders. URLs from City Research Online may be freely distributed and linked to.

**Reuse:** Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

---

City Research Online:

<http://openaccess.city.ac.uk/>

[publications@city.ac.uk](mailto:publications@city.ac.uk)

---

Article

## Immunotherapy with an HIV-DNA Vaccine in Children and Adults

Paolo Palma <sup>1,2,†,\*</sup>, Lindvi Gudmundsdotter <sup>3,4,†</sup>, Andrea Finocchi <sup>1,2</sup>, Lars E. Eriksson <sup>5,6,7</sup>, Nadia Mora <sup>2</sup>, Veronica Santilli <sup>2</sup>, Angela Aquilani <sup>2</sup>, Emma C. Manno <sup>2</sup>, Paola Zangari <sup>2</sup>, Maria Luisa Romiti <sup>2</sup>, Carla Montesano <sup>8</sup>, Alba Grifoni <sup>8</sup>, Andreas Brave <sup>3</sup>, Karl Ljungberg <sup>3</sup>, Pontus Blomberg <sup>9</sup>, Stefania Bernardi <sup>1</sup>, Eric Sandström <sup>10</sup>, Bo Hejdeman <sup>10</sup>, Paolo Rossi <sup>1,2,‡</sup> and Britta Wahren <sup>3,‡</sup>

<sup>1</sup> University Department of Pediatrics (DPUO), Unit of Immune and Infectious Diseases, Children's Hospital Bambino Gesù, Piazza S. Onofrio 4, 00165 Rome, Italy; E-Mails: andrea.finocchi@opbg.net (A.F.); stefania.bernardi@opbg.net (S.B.); paolo.rossi@opbg.net (P.R.)

<sup>2</sup> Chair of Pediatrics, Department of System Medicine, University of Rome Tor Vergata, 00133 Rome, Italy; E-Mails: nadia.mora@hotmail.it (M.N.); veronica.santilli@hotmail.it (V.S.); angela.aquilani@libero.it (A.A.); emma\_m@hotmail.it (E.C.M.); paolazangari@hotmail.com (P.Z.); romiti@med.uniroma2.it (M.L.R.)

<sup>3</sup> Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden; E-Mails: Lindvi.Gudmundsdotter@affibody.se (L.G.); andreas.brave@folkhalsomyndigheten.se (A.B.); karl.ljungberg@ki.se (K.L.); Britta.Wahren@ki.se (B.W.)

<sup>4</sup> Affibody AB, 17163 Solna, Sweden

<sup>5</sup> Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge 171 77, Sweden; E-Mail: Lars.Eriksson@ki.se

<sup>6</sup> Department of Infectious Diseases, Karolinska University Hospital, Stockholm 171 77, Sweden

<sup>7</sup> School of Health Sciences, City University London, London EC1V 0HB, UK

<sup>8</sup> Department of Biology, University of Rome Tor Vergata, 00133 Rome, Italy; E-Mails: montesano@uniroma2.it (C.M.); alba.grifoni@uniroma2.it (A.G.)

<sup>9</sup> Vecura, Clinical Research Center, Karolinska University Hospital, Stockholm 141 86, Sweden; E-Mail: pontus.blomberg@karolinska.se

<sup>10</sup> Venhälsan, Karolinska Institutet (KI), Södersjukhuset, Stockholm 118 83, Sweden; E-Mails: eric.sandstrom@sodersjukhuset.se (E.S.); bo.hejdeman@sodersjukhuset.se (B.H.)

† Shared first authorship.

‡ Shared last authorship.

\* Author to whom correspondence should be addressed; E-Mail: paolo.palma@opbg.net.

*Received: 27 February 2014; in revised form: 26 June 2014 / Accepted: 27 June 2014 /*

*Published: 17 July 2014*

---

**Abstract:** Therapeutic HIV immunization is intended to induce new HIV-specific cellular immune responses and to reduce viral load, possibly permitting extended periods without antiretroviral drugs. A multigene, multi-subtype A, B, C HIV-DNA vaccine (HIVIS) has been used in clinical trials in both children and adults with the aim of improving and broadening the infected individuals' immune responses. Despite the different country locations, different regimens and the necessary variations in assays performed, this is, to our knowledge, the first attempt to compare children's and adults' responses to a particular HIV vaccine. Ten vertically HIV-infected children aged 4–16 years were immunized during antiretroviral therapy (ART). Another ten children were blindly recruited as controls. Both groups continued their antiretroviral treatment during and after vaccinations. Twelve chronically HIV-infected adults were vaccinated, followed by repeated structured therapy interruptions (STI) of their antiretroviral treatment. The adult group included four controls, receiving placebo vaccinations. The HIV-DNA vaccine was generally well tolerated, and no serious adverse events were registered in any group. In the HIV-infected children, an increased specific immune response to Gag and RT proteins was detected by antigen-specific lymphoproliferation. Moreover, the frequency of HIV-specific CD8<sup>+</sup> T-cell lymphocytes releasing perforin was significantly higher in the vaccinees than the controls. In the HIV-infected adults, increased CD8<sup>+</sup> T-cell responses to Gag, RT and viral protease peptides were detected. No augmentation of HIV-specific lymphoproliferative responses were detected in adults after vaccination. In conclusion, the HIV-DNA vaccine can elicit new HIV-specific cellular immune responses, particularly to Gag antigens, in both HIV-infected children and adults. Vaccinated children mounted transient new HIV-specific immune responses, including both CD4<sup>+</sup> T-cell lymphoproliferation and late CD8<sup>+</sup> T-cell responses. In the adult cohort, primarily CD8<sup>+</sup> T-cell responses related to MHC class I alleles were noted. However, no clinical benefits with respect to viral load reduction were ascribable to the vaccinations alone. No severe adverse effects related to the vaccine were found in either cohort, and no virological failures or drug resistances were detected.

**Keywords:** HIV-1; DNA vaccine; children and adults

---

## 1. Introduction

Highly active antiretroviral therapy (ART) is the principal tool to control HIV infection [1]. The benefits of ART regimens in children and adults are widely demonstrated in terms of viral control and immune reconstitution [2]. The main persisting problems are the life-long need for strict therapeutic adherence, the emergence of side effects, the risk of developing resistance and the cost of medication [3–6].

In the clinical context, new therapeutic approaches, such as HIV vaccines, have been investigated in recent years in both children and adults [1,7–11]. The goal of immune intervention in HIV infection is to restore immunocompetence and reverse the anergy-like situation in infected individuals. This, in turn, could reduce viral load and the virus-producing cells in viral reservoirs, permitting extended periods without ART. Therapeutic vaccines have been tested extensively, such as envelope proteins [12–14], killed virus preparations [15,16], pox immunogens, such as ALVAC (a replication-deficient vaccine vector derived from canary pox) [17], peptides [18] and HIV-expressing DNA plasmids [9,19–25]. The only one of these trials to indicate a clinical effect and short-term improved survival was repeated gp160 glycoprotein immunization, including 835 HIV-infected individuals on no or low-efficiency antiretrovirals [14].

DNA vaccines mimic live attenuated vaccines, inducing innate, humoral and cellular immune responses, without the risks associated with the administration of infectious or attenuated agents. The multigene, multi-subtype HIV-DNA vaccine (HIVIS) is a combination of plasmid DNA constructs, encoding several components, including structural and non-structural genes from several subtypes of HIV-1 [26]. This HIV-DNA has been studied extensively in terms of preclinical safety and immunogenicity [27–31].

The objective of the present study is to compare the findings obtained in two principal trials conducted in HIV vertically-infected children and chronically-infected adults in terms of feasibility, safety and immunogenicity. Despite the different country locations, different regimens and the necessary variations in assays performed, this is, to our knowledge, the first attempt to compare children's and adults' responses to a particular HIV vaccine.

## 2. Experimental

### 2.1. Study Subjects and Trial Design

The PEDVAC (acronym for our paediatric HIV vaccine trial) trial included twenty HIV-1 subtype B vertically-infected children (4–16 years of age) on stable antiretroviral regimen for at least 6 months with HIV-1 RNA <50 copies/mL and stable CD4+ T-cell counts ( $\geq 400$  cells/mm<sup>3</sup> or 25%) over 12 months of follow-up (Table 1). Patients were randomized into two arms: a control group of 10 children who continued their previous antiretroviral regimen (Arm A) and received no placebo, as determined by the local ethical committee, and a group of 10 children immunized intramuscularly with the HIV-DNA vaccine in addition to their previous ART regimen (Arm B). In the PEDVAC trial, the patients were kept on ART for the duration of the study [9]. In the children, immunizations were administered by intramuscular injection at Weeks 0, 4 and 12 with a boosting dose at Week 36.

In the adult study (Dermavax), twelve chronically HIV-1 subtype B-infected male patients (29–56 years of age) on an antiretroviral regimen (ART) with viral loads of <50 copies/mL and CD4+ T-cell counts of >450 cells/mm<sup>3</sup> for at least 6 months were enrolled (Table 1). The adults were randomized into three groups, modelled on a successful study in macaques [32]: a control group of 4 patients (Group 1), a group of 5 patients immunized with HIV-DNA plasmids (Group 2) and a group of 3 subjects immunized with HIV-DNA plasmids and treated orally with hydroxyurea daily (Group 3) until Visit 10 [22]. Hydroxyurea was added to decrease immune activation, but in order to identify vaccine-specific reactivities, Groups 2 and 3 were handled as a single group of 8 vaccinated adults. The immunizations were performed during three cycles of 7 weeks of ART followed by four weeks of therapy interruption. In adults, dermal vaccinations were given at Weeks 4, 6, 15, 17, 26 and 28. After the third cycle of ART, including the last two immunizations, the patients were allowed to continue long-term treatment interruption until they showed signs of immunological or virological failure. In both cohorts, HIV viral load, CD4+ T-cell count and other immunological samplings were periodically performed.

**Table 1.** Demographic characteristics of paediatric and adult cohorts.

Characteristics	Paediatric Study (N = 20)	Adult Study (N = 12)
Age ± SD, year	11.6 ± 2.6	41.7 ± 6.8
Sex, no. male/female	7/13	12/0
Caucasian race, no. (%)	18 (90%)	10 (83%)
Placebo/HIV-DNA vaccine, no.	10/10	4/8
CD4+ T-cells/mm <sup>3</sup> at baseline, mean ± SD	763.6 ± 231.1	685.9 ± 137.7
CD4+ T-cells/mm <sup>3</sup> at last visit, mean ± SD	803.1 ± 237.5	545.4 ± 148.1
HIV-RNA level at baseline copies/mL, mean	<50	<50
HIV-RNA level at last visit copies/mL, mean	<50	<50
Duration of vaccination: duration of study weeks	36:96	28:60
Antiretroviral therapy during study, weeks	96	21
Observation period, weeks	156	300

## 2.2. Vaccine Formulation and Administration Technology

In the PEDVAC trial, two preparations of HIV-DNA plasmids were used: (1) DNA plasmids (2 mg/mL) encoding HIV Env A, B, C and Rev B in Ampoule 1; and (2) DNA plasmids (2 mg/mL) encoding HIV gp 160 Gag A, B and RTmut B in Ampoule 2. The development of the expression vectors containing the HIV-1 envelope genes *gp160 A, B and C* (pKCMVgp160A, pKCMVgp160B, pKCMVgp160C); *rev* (pKCMVrev); reverse transcriptase *RTmut* (pKCMVRTmut); *p37BA* and *p37B* (pKCMVp37BA, pKCMVp37B) were previously described [29,33,34].

Each child received 1.2 mL of *Env-Rev DNA* (from Ampoule 1) in the left arm and 0.8 mL of *Gag-RTmut DNA* (from Ampoule 2) in the right arm, amounting to a total of 4 mg of HIV-DNA by intramuscular injection at the two deltoid sites at each visit. In total, each child received 16 mg HIV-DNA given by needle intramuscularly.

The HIV-DNA vaccine plasmids used in the adult study were the same combinations of: (1) gp160 subtypes A, B and C together with Rev subtype B; and (2) Gag subtypes A and B together with RTmut

subtype B (see above). The plasmid combinations were delivered separately, formulated in polyethylene imine mannose (PEIm) and dextrose solution [35,36]. For each vaccination, 3.2 mL vaccine (a total amount 0.4 mg at each visit) or placebo (only formulation solution) were administered at four skin sites that had been freed of the superficial layer of keratinocytes [22,37]. In total, each adult received 2.4 mg of HIV-DNA given directly on large areas of scraped skin, intended to directly reach dendritic cells [37].

### 2.3. Safety Evaluation

In the paediatric study, patients or their parents recorded, in a self-administered diary card, the occurrence and severity of solicited local and systemic events, using a standard scale to grade reactions. In both studies, physical safety evaluations were performed before vaccination and at each visit. Immediate local and systemic reactions were observed during the first hour after the HIV-DNA application. All medical events were recorded as possible adverse events and were graded by the principal investigator as to their severity and relationship to the immunization. The standard AIDS Clinical Trials Group (ACTG) grading scale was used to evaluate adverse events in both studies.

### 2.4. Laboratory Assays

#### 2.4.1. CD4+ T-Cell Counts, Plasma HIV-1 RNA Levels and Cell-Associated HIV-DNA Quantification

The CD4+ T-cell number in blood was measured by flow cytometry. Viral load in plasma was measured by the Quantiplex HIVRNA 2.0 bDNA Assay, Chiron Diagnostic Corporation, Emeryville, CA, USA, and the viral load of lymphocytes by HIV-DNA quantification. In addition, an ultrasensitive method was used to quantify virus down to 1 viral RNA copy/mL. The plasma was pelleted, the pellet virus extracted in 1/8 of the original volume and assayed by reverse transcription and PCR following the method for Amplicor HIV-1 monitor v. 1.5 (Roche Molecular Systems, Pleasanton, CA, USA). In plasma of adults, the Roche Diagnostic System with a lower limit quantification of 50 copies/mL of plasma viral load was used.

#### 2.4.2. Cellular Immune Responses

In both studies, the immune response to HIV-DNA vaccine was evaluated by lymphoproliferation and other functional assays. Lymphoproliferation assays were performed in both adults and children on fresh peripheral blood mononuclear cells (PBMC) cultured with HIV antigens and mitogens, as described below [9,22].

Briefly, in children, PBMC were cultured in 96-well plates for 7 days with aldrithiol-2 (AT-2)-treated HIV-1 MN virions subtype B at 2.5 µg/mL and non-viral control antigen SUPT1 microvesicles at 2.5 µg/mL (kindly provided by Dr. J. Lifson, SAIC Frederick, Inc., Frederick, MD, USA), recombinant reverse transcriptase (rRT) subtype B at 0.5 µg/mL, rp24 at 0.5 µg/mL and recall antigen cytomegalovirus (CMV) at 0.5 µg/mL and *Candida albicans* at 0.5 µg/mL (Nanogen, Torino, Italy). Results are shown as mean values of duplicates and are expressed as counts per minute (cpm). The stimulation index (SI) was defined as previously described [9,38] and was considered to be positive when higher than 3.

In the paediatric cohort, functional tests further consisted of intracellular staining (ICS) after stimulation with a combination of HIV-1 proteins [9]. Heparinized blood was incubated with 1 µg each of anti-CD28 and anti-CD49d monoclonal antibodies (mabs) and 1 µg of a protein pool consisting of recombinant proteins representing the vaccine sequences of HIV-1 RT (Clade B), HIV-1 p17/24 (Clade B), HIV-1 p17/24 (Clade C) or mabs only, for 16 h. After 2 h, 10 µg/mL of brefeldin A (Sigma-Aldrich, St. Louis, MO, USA) were added. After 14 h, cells were stained with anti-CD3, anti-CD4 and anti-CD8 antibodies. Red blood cells were lysed with BD FACS Lysing solution (BD, San José, CA, USA), fixed with 4% paraformaldehyde and washed. Lymphocytes were stained with anti-IFN-γ mab and analysed with a FACS Canto II. Results were expressed as the percentage of cytokine-producing CD3+, CD4+ and CD8+ T-cells. A percentage of cytokine-secreting cells of HIV-stimulated cultures higher than or equal to 0.02% above the unstimulated cultures was considered positive. A percentage of cytokine-producing control cells lower than 0.06% was requested for evaluation [9,38].

In the adult cohort, ELISpot was performed with HIV Env, Gag and Pol peptide pools (NIH repository, MD) [22]. ELISpot assays were performed with pre-coated anti-IFN-γ and anti-perforin ELISpot plates (Mabtech, Nacka Strand, Sweden), using fresh PBMC and PBMC depleted of CD8+ T-cells. HIV-1 subtype B peptide pools corresponding to Env, Gag and Pol (NIH repository, MD) were used at 2.5 µg/mL. Plates were incubated for 22 h for IFN-γ ELISpot and 44 h for perforin ELISpot at 37 °C. The results were expressed as the mean number of spot-forming cells (SFC) per 10<sup>6</sup> PBMCs. ELISpot responses were considered positive if the number of spot-forming cells was >4 times the background and >55 SFC/10<sup>6</sup> PBMCs.

#### 2.4.3. Humoral Immune Responses

Binding antigen-specific antibodies to HIV-1 subtype B gp160 (Protein Sciences Corporation, Meriden, CT, USA) or recombinant HIV-1 subtype B p24 Gag (CFAR, Potters Bar, UK) were evaluated in ELISA-based assays for both cohorts [11].

#### 2.5. Ethics

The protocols were approved by the Ethical Committee of the Children's Hospital Bambino Gesù of Rome and by the Karolinska Institutet of Stockholm, for the paediatric and adult studies, respectively. Written informed consent was obtained from all participants and/or their parents.

#### 2.6. Statistical Analysis

Statistical calculations were performed in GraphPad Prism Software version 5.00 and IBM SPSS Statistics v. 22. Statistical significance was accepted if  $p < 0.05$ . Comparisons between the paediatric and adult cohorts were calculated by Mann–Whitney  $U$  tests within cohorts and between cohorts.

### 3. Results

#### 3.1. Patients Enrolled

The characteristics of the two cohorts are presented in Table 1.

#### 3.2. Safety

The HIV-DNA vaccine was generally well tolerated, and only one serious adverse event was detected during the studies in the adult cohort (Table 2).

**Table 2.** Reported adverse events of vaccinees.

	Grade 1		Grade 2		Grade 3	
	Local	Systemic	Local	Systemic	Local	Systemic
Vaccinated children ( <i>n</i> = 10)	12	16	2	6	0	0
Vaccinated adults ( <i>n</i> = 8)	39	17	0	4	1	0

In the paediatric study, a total of 36 adverse events related to vaccination were recorded from the first injection to one month after the last one with an excess of local events in the vaccine group. All reactions in children or adults were graded as mild or moderate, and no accumulation of adverse events was registered. In the vaccinated adult group, a total of 61 adverse events were detected during the study. Only one Grade 3 event was registered in a patient in the adult cohort (Table 2). This was a rash attributed to hydroxyurea treatment. This patient was continued on vaccine only [22]. The duration until ART was re-initiated after the third vaccination and STI cycle, was 15 months for vaccinated (range 20–185 weeks) and 18 months for placebo (range 20–145 weeks), a non-significant difference (Appendix Figure A1). None of the paediatric or adult participants failed any vaccination.

#### 3.3. CD4+ T-Cell Counts, Plasma HIV-1 RNA Levels and Cell-Associated HIV-DNA Quantification

In the paediatric cohort, no patient experienced virological failure. In three of the twenty children included (one in the control group and two in the vaccinated group), a single viral blip was detected (not exceeding 1000 copies/mL of plasma HIV-RNA), which returned to below 50 copies/mL of viral RNA at the following determination. CD4+ T-cell counts remained above 400 cells/mm<sup>3</sup> over time.

In the adult cohort, an increased plasma viral load was observed during the STI phases and after the final interruption of ART in all, except two patients (one placebo and one vaccinee), the viral loads of whom remained low during the short-term STIs (Appendix Figure A1). The viral peaks during STIs ranged from below 50 viral genomes/mL to 105 viral genomes/mL, and virus replication recurred during the second and third STIs (Appendix Figure A1). The differences between the highest levels (peaks) of virus during the three cycles of STI were not statistically significant between the vaccine and the placebo group. Of particular interest is that the plateau levels of virus after the final third STI at months 1, 2, 3, 4, 5 were significantly lower than the viral set points before the first initiation of antiretroviral therapy for the whole adult group (*p* = 0.003) [22]. The mean viral set point for all adults was 105, while median levels following the last STI slowly increased from 104.1 to 104.4 viral genomes/mL. The viral levels following the last STI, thus, had significantly decreased, when compared

to the original viral set point. Viral levels were calculated as median values of consecutive measurements following the third STI ([22] and Appendix Figure A1).

We have previously shown that drug-resistance did not develop [22]. As expected, the CD4+ T-cell counts decreased during the first two STIs and these levels were comparable in the vaccinated and placebo groups. All patients finally resumed antiretroviral therapy without significant time differences between placebo and vaccinees (Appendix Figure A1).


### 3.4. HIV-Specific Immune Responses

#### 3.4.1. Cellular Immune Responses

Smaller volumes of samples could be obtained from children compared to adults, and the frequency of sampling was lower in the child cohort. It is also likely that the results of a particular assay may vary between sites. We have therefore compared immune responses to the baseline responses of each cohort, rather than comparing actual values between cohorts.

In the paediatric cohort, higher lymphoproliferative responses to Gag proteins (HIV-1 MN and p24, both representing HIV-1 Gag subtype B) were observed in the vaccinees compared to controls (Figure 1a, b).

**Figure 1.** Lymphocyte proliferation assays of the paediatric cohort, showing responses to (a) the HIV-1 MN antigen; (b) the p24 antigen; (c) the RT antigen (summarized, sum or total, for Weeks 12–72); (d) the intracellular staining (ICS) data of perforin-releasing CD8+ T-cells are shown.






after vaccination. Low or no ELISpot reactivity was noted by measuring IFN- $\gamma$  in response to single Gag, Env or RT peptides.

The adult vaccine group had a higher net gain of HIV-specific IFN- $\gamma$  responses from baseline to Week 10 compared to the placebo group ( $p = 0.028$ , Figure 3). The levels of perforin-secreting cells were high at baseline. There were distinct increases of peptide-specific responses as measured by ELISpot IFN- $\gamma$  to peptides representing HIV-1 subtype B. Altogether, 28 responses occurred in the vaccinated cohort and 11 in the placebo group. They were tentatively allocated to alleles HLA (Human Leucocyte Antigen) A\*0201, A\*0301, B\*35 and B\*5701, among others, and occurred for several peptides summarized to represent Gag, RT and viral protease PR (Figure 3) [22]. We must therefore conclude that vaccination, together with STI, permitting viral stimulation, contributed to the detection of the novel HIV-specific CD8+ T-cell responses.

**Figure 3.** Increases of HIV-specific and recall-induced IFN- $\gamma$  ELISpot responses in placebo and vaccine recipients in the adult cohort. Changes (Ch.) in HIV-specific IFN- $\gamma$  (IFN $\gamma$ ) responses to Gag, RT and protease peptides at visit 10 are shown. The baseline responses have been subtracted. The vaccine group had more prominent increases of HIV-specific IFN- $\gamma$  responses of peptide reactivities than the placebo group (Mann–Whitney  $U$  test,  $p = 0.028$ ).



### 3.4.2. Humoral Responses

In children, the vaccination protocol did not appear to affect binding antibody levels. In the adult cohort, gp160 and p24 titres were high and remained at the same level in all, except two vaccinated patients, who significantly increased their titres to both Env and Gag protein antigens. These two individuals raised their antibody titre to gp160 subtype B 20- or 100-fold and antibody responses to Gag p24 subtype B 10- or 300-fold, respectively.

## 4. Discussion

This is a comparative study focusing on HIV-DNA vaccination in infected children and adults. Both the paediatric and the adult trials separately demonstrated feasibility, safety and moderate immunogenicity [9,11,22]. Very importantly, genetic vaccination was not observed to increase virus amounts, as had been feared [40]. We can thus conclude that the HIV-DNA vaccine, called HIVIS, is a

safe vaccine strategy in paediatric and adult HIV-infected individuals. We have not observed increased viral replication above what was reported in non-vaccinated controls. No major adverse events occurred during or after the vaccination schedules, either in paediatric or in adult cohorts, confirming the safety profile of genetic vaccination, also reported in healthy subjects [39,41].

In children, due mainly to a more preserved immune system and to the continuation of ART during the study period, a good virological control and maintenance of CD4<sup>+</sup> T-cell values were observed compared to the adult study. Our sensitive viral RNA and DNA assays, however, could measure very low viral loads, varying around 1–10 RNA viral copies/mL of blood of both vaccinated and control children. Thus, the HIV-specific immune response did not significantly influence viral replication rates during ART, even at very low viral levels.

In contrast, in the adult cohort, a rebound of plasma viral load and decreased CD4<sup>+</sup> T-cell levels during STI periods were observed, which were similar to that of the adult placebo patients. Following the last STI, all adults had quite a long period without drug, a median of 15–18 months, similar for vaccinated and placebo recipients. The cycles of treatment interruptions in the adult cohort induced changes in several parameters of innate immunity. We noted increased TLR7/8-triggered secretion of IL-12 and IFN- $\alpha$ , as well as TLR9-triggered secretion of IL-12. On the other hand, we noted a reduction of TLR9 stimulated IFN- $\alpha$  plasmocytic and myeloid dendritic cells [42]. These results suggest that the consequences of short-term STI include dysregulated TLR responses and fluctuations in the frequencies of circulating dendritic cells. Possibly these factors, related to innate immunity, contributed to the rapid increase in viral replication in all, except two, adult individuals during the first two STIs.

In HIV-infected children and adults, novel antigen-specific cellular immune responses were elicited after vaccination. In the HIV-infected children, we noted increased specific cellular immune responses to Gag antigens (HIV-1 strain MN and p24) and to RT antigens. These reactions were detected by lymphoproliferation assays after vaccination, indicating primarily a CD4<sup>+</sup> T-cell-specific response. Gag-specific T-cell responses have been correlated with lower levels of viral load in chronically infected patients [43–46]. Lymphoproliferative responses were, however, not observed in the adult cohort. The difference in antigen-specific lymphoproliferation responses between the children and adults may be due to the length of exposure to the endogenous viral infection, which, untreated, had occurred for a longer time in the adults.

In some studies, RT-specific T-cell responses have been reported to be of protective value in HIV-infected individuals [47,48]. In children, RT lymphoproliferative responses were detected after vaccination, whereas no such reactivities were induced by the same HIV-DNA vaccine in healthy adults. The lymphocytes of vaccinated children appeared more reactive with RT proteins (CD4<sup>+</sup> T-cell related) than vaccinated adults, who instead responded better to RT peptides (CD8<sup>+</sup> T-cell related). This phenomenon might be due to a more intact immunological status of the children in this study [49]. According to worldwide HIV treatment guidelines, the children's cohort started ART during the first year of life, while the adults started ART when CD4<sup>+</sup> T-cell values were below 350 cells/mm<sup>3</sup>. The delayed antiretroviral therapy in adults thus results in a more pronounced immune exhaustion compared to early-treated children.

In the paediatric cohort, an increase of HIV-specific CD8<sup>+</sup> T-cells secreting perforin was detected after three vaccine doses and after the late boosting with HIV-DNA. Novel CD8<sup>+</sup> T-cell-specific

responses to HIV Gag and RT were seen in infected vaccinated adults and could be typed to identify responding alleles [22].

No significant increases of antigen-specific humoral responses were detected in children and in only two of the adults after vaccinations. These data are disappointing, but consistent with the performance of other stand-alone DNA vaccines delivered to date. In healthy adults, on the other hand, priming with this HIV-DNA vaccine used in combination with vaccinia-derived boosts, has evoked potent humoral responses after two HIV-MVA boosts [39,41,50].

The functional immune responses thus appear to be different in the two cohorts, probably reflecting many parameters, such as age, the duration of the HIV infection, the timing of ART initiation and the duration of the ART. With increasing age, the human immune system undergoes characteristic changes, termed immunosenescence, leading to insufficient protection following vaccination [51]. Immunosenescence is also observed in chronic HIV infection [52–54]. Therefore, biological age and the duration of HIV infection negatively influence the immune responses in the adult cohort, in addition to long periods with high viral loads before therapy, as mentioned above [55].

There are possibilities to increase the immunological pressure against virus-producing cells. One might apply a prime-boost immunization schedule with HIV-DNA followed by modified vaccinia-based boosts (HIV-MVA), which has been highly successful to induce both cellular and humoral immune responses in healthy adults [39,41,50]. In neither our childhood cohort nor in the adult cohort was it considered safe or ethical at that time to progress with attenuated vaccinia-based immunotherapy. Another boosting strategy may be a protein, which would primarily induce CD4+ T-cell and B-cell responses.

The aims of the present studies were to identify modes by which repeated immunizations can work together with, or substitute for, drugs during certain sensitive periods in the life of the HIV-infected individual. Young adults, particularly in adolescence, could benefit from periods of reduced treatment [56]. Such attempts must be monitored closely.

## 5. Conclusions

In conclusion, the HIV-DNA vaccine can elicit new HIV-specific cellular immune responses, particularly to Gag antigens, in infected children and adults, albeit with different profiles. Vaccinated HIV-infected children mounted a CD4+ T-cell-related HIV-specific immune response, whereas the infected adults primarily showed CD8+ T-cell responses related to their MHC class I alleles. None of these immunization schedules was potent enough to change the viral load dynamics over time or during therapy interruptions in HIV-infected adults. Additional studies and new virological tools are required to evaluate the impact of vaccination on the viral reservoirs in children before periods of ART interruption are attempted in this population.

## Acknowledgments

We thank all of the patients and their families for their enthusiastic collaboration and the nursing staff of trials at both Bambino Gesù in Rome and Södersjukhuset in Stockholm for their excellent work.

We thank Jennifer Faudella and Gunnel Engström for their precious administrative work.

## Author Contributions

Paolo Palma, Stefania Bernardi, Eric Sandström, Bo Hejdeman, Britta Wahren and Paolo Rossi designed and led the clinical studies. Andrea Finocchi, Veronica Santilli, Angela Aquilani, Emma C. Manno, Paola Zangari, Alba Grifoni, Stefania Bernardi took part in the clinical assessments of the paediatric cohort. Lindvi Gudmundsdotter, Maria Luisa Romiti, Carla Montesano, Andreas Brave, Karl Ljungberg designed and performed the immunology and experimental choice of immunogens, Pontus Blomberg and Britta Wahren designed and produced the HIV-DNA vaccine. Lars E. Eriksson helped with statistical analysis, Paolo Palma, Nadia Mora and Britta Wahren analysed and wrote the comparative study.

## Conflicts of Interest

The PEDVAC study was supported by grants from the Swedish Research Council and the FP6 European Union Europrise network of excellence for the development of HIV vaccine and microbicides (Grant No. 037611) and by the Italian Ministry of Health, Rome (Finalized Project 2011); Italian Health Institute, Rome (AIDS 40H91-ISS/OPBG). The reagents, ARP631 Rec HIV-1 RT, ARP694 HIV p17/24 Clade B, ARP695 HIV-1 p17/24 Clade C, ARP698 HIV-1 UG37 gp140 Clade A, ARP699 CN54 gp140 Clade C, ARP680 Rec HIV-1 rgp41 and EVA620 HIV-1 p24 Clade B, were provided by the Center for AIDS Reagents, NIBSC (National Institute for Biological Standards and Control), UK, Programme EVA (European HIV Vaccine Antigens) supported by the European Community by FP6/7 Europrise Network of Excellence, AVIP (Aids Vaccine Integrated Project) and NGIN (Next Generation HIV-1 Immunogens) consortia and the Bill and Melinda Gates Project GHRC-CAVD (Global HIV Vaccine Research- Collaboration for AIDS Vaccine Discovery). Reagents were also donated by D. Stammers, GLAXO, Wellcome (ARP631), FIT BIOTECH Oyj Plc Eesti Filiaal, Tartu, ESTONIA (ARP694 and ARP695), Polymun, Vienna, Austria (ARP698 and ARP699), Immunogenetics Inc. (EVA620). SD and PP were supported by the FP6 European Union Europrise network of excellence. This is a non-profit study, and the funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.

The adult cohort study was funded by the European Union (INCO-DEV A4 ICFP501A4PR03, AVIP503487), the Swedish Research Council (Vetenskapsradet, K2004-16x-07743-19) and Lakare mot AIDS Forskningsfond (04-050301 and 01-051101). The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.

## References

1. Garcia, F.; León, A.; Gatell, J.M.; Plana, M.; Gallart, T. Therapeutic vaccines against HIV infection. *Hum. Vaccines Immunother.* **2012**, *8*, 569–581.
2. Patel, K.; Hernán, M.A.; Williams, P.L.; Seeger, J.D.; McIntosh, K.; Dyke, R.B.; Seage, G.R., III. Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 Years and counting. *Clin. Infect. Dis.* **2008**, *46*, 1751–1760.
3. Piloya, T.; Bakeera-Kitaka, S.; Kekitiinwa, A.; Kamya, M.R. Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: A cross sectional study. *J. Int. AIDS Soc.* **2012**, *15*, doi:10.7448/IAS.15.2.17427.

4. Haberer, J.; Mellins, C. Pediatric adherence to HIV antiretroviral therapy. *Curr. HIV/AIDS Rep.* **2009**, *6*, 194–200.
5. Gakhar, H.; Kamali, A.; Holodniy, M. Health-related quality of life assessment after antiretroviral therapy: A review of the literature. *Drugs* **2013**, *7*, 651–672.
6. Feleke, Y.; Fekade, D.; Mezegebu, Y. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients. *Ethiop. Med. J.* **2012**, *50*, 221–230.
7. Montagnier, L. 25 years after HIV discovery: Prospects for cure and vaccine. *Virology* **2010**, *397*, 248–254.
8. Gudmundsdotter, L.; Sjödin, A.; Boström, A.C.; Hejdeman, B.; Theve-Palm, R.; Alaeus, A.; Lidman, K.; Wahren, B. Therapeutic immunization for HIV. *Springer Semin. Immunopathol.* **2006**, *28*, 221–230.
9. Palma, P.; Romiti, M.L.; Li Pira, G.; Montesano, C.; Mora, N.; Aquilani, A.; Santilli, V.; Tchidjou, H.K.; Ivaldi, F.; Giovannelli, L.; *et al.* The PEDVAC trial: Preliminary data from the first therapeutic DNA vaccination in HIV-infected children. *Vaccine* **2011**, *29*, 6810–6816.
10. Gandhi, R.T.; O'Neill, D.; Bosch, R.J.; Chan, E.S.; Bucy, R.P.; Shopis, J.; Baglyos, L.; Adams, E.; Fox, L.; Purdue, L.; *et al.* A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. *Vaccine* **2009**, *27*, 6088–6094.
11. Palma, P.; Romiti, M.L.; Montesano, C.; Santilli, V.; Mora, N.; Aquilani, A.; Dispinseri, S.; Tchidjou, H.K.; Montano, M.; Eriksson, L.E.; *et al.* Therapeutic DNA vaccination of vertically HIV-infected children: Report of the first pediatric randomised trial (PEDVAC). *PLoS One* **2013**, *8*, e79957.
12. Birx, D.L.; Loomis-Price, L.D.; Aronson, N.; Brundage, J.; Davis, C.; Deyton, L.; Garner, R.; Gordin, F.; Henry, D.; Holloway, W.; *et al.* Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. *J. Infect. Dis.* **2000**, *181*, 881–889.
13. Redfield, R.R.; Birx, D.L.; Ketter, N.; Tramont, E.; Polonis, V.; Davis, C.; Brundage, J.F.; Smith, G.; Johnson, S.; Fowler, A.; *et al.* A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research. *N. Engl. J. Med.* **1991**, *324*, 1677–1684.
14. Sandstrom, E.; Wahren, B.; Nordic VAC-04 Study Group. Therapeutic immunisation with recombinant gp160 in HIV-1 infection: A randomised double-blind placebo-controlled trial. *Lancet* **1999**, *353*, 1735–1742.
15. Maino, V.C.; Suni, M.A.; Wormsley, S.B.; Carlo, D.J.; Wallace, M.R.; Moss, R.B. Enhancement of HIV type 1 antigen-specific CD4+ T cell memory in subjects with chronic HIV type 1 infection receiving an HIV type 1 immunogen. *AIDS Res. Hum. Retrovir.* **2000**, *16*, 539–547.
16. Moss, R.B.; Giermakowska, W.; Wallace, M.R.; Savary, J.; Jensen, F.; Carlo, D.J. T-helper-cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1-infected subjects vaccinated with HIV-1 immunogen (Remune). *Clin. Diagn. Lab. Immunol.* **2000**, *7*, 724–727.

17. Autran, B.; Murphy, R.L.; Costagliola, D.; Tubiana, R.; Clotet, B.; Gatell, J.; Staszewski, S.; Wincker, N.; Assoumou, L.; El-Habib, R.; *et al.* Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). *AIDS* **2008**, *22*, 1313–1322.
18. Kran, A.M.; Sørensen, B.; Nyhus, J.; Sommerfelt, M.A.; Baksaas, I.; Bruun, J.N.; Kvale, D. HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x). *AIDS* **2004**, *18*, 1875–1883.
19. Calarota, S.; Bratt, G.; Nordlund, S.; Hinkula, J.; Leandersson, A.C.; Sandström, E.; Wahren, B. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. *Lancet* **1998**, *351*, 1320–1325.
20. MacGregor, R.R.; Boyer, J.D.; Ugen, K.E.; Tebas, P.; Higgins, T.J.; Baine, Y.; Ciccarelli, R.B.; Ginsberg, R.S.; Weiner, D.B. Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral “blips”. *Vaccine* **2005**, *23*, 2066–2073.
21. Rosenberg, E.S.; Graham, B.S.; Chan, E.S.; Bosch, R.J.; Stocker, V.; Maenza, J.; Markowitz, M.; Little, S.; Sax, P.E.; Collier, A.C.; *et al.* Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection. *PLoS One* **2010**, *5*, e10555.
22. Gudmundsdóttir, L.; Wahren, B.; Haller, B.K.; Boberg, A.; Edbäck, U.; Bernasconi, D.; Butto, S.; Gaines, H.; Imami, N.; Gotch, F.; *et al.* Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial. *Vaccine* **2011**, *29*, 5558–5566.
23. Lisziewicz, J.; Bakare, N.; Calarota, S.A.; Banhegyi, D.; Szlavik, J.; Ujhelyi, E.; Toke, E.R.; Molnar, L.; Lisziewicz, Z.; Autran, B.; *et al.* Single DermaVir immunization: Dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals. *PLoS One* **2012**, *7*, e35416.
24. Casazza, J.P.; Bowman, K.A.; Adzaku, S.; Smith, E.C.; Enama, M.E.; Bailer, R.T.; Price, D.A.; Gostick, E.; Gordon, I.J.; Ambrozak, D.R.; *et al.* Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. *J. Infect. Dis.* **2013**, *207*, 1829–1840.
25. Rodriguez, B.; Asmuth, D.M.; Matining, R.M.; Spritzler, J.; Jacobson, J.M.; Mailliard, R.B.; Li, X.D.; Martinez, A.I.; Tenorio, A.R.; Lori, F.; *et al.* Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: Results of the ACTG 5176 trial. *J. Acquir. Immune Defic. Syndr.* **2013**, *64*, 351–359.
26. Brave, A.; Ljungberg, K.; Boberg, A.; Rollman, E.; Isaguliant, M.; Lundgren, B.; Blomberg, P.; Hinkula, J.; Wahren, B.; *et al.* Multigene/Multisubtype HIV-1 Vaccine Induces Potent Cellular and Humoral Immune Responses by Needle-Free Intradermal Delivery. *Mol. Ther.* **2005**, *12*, 1197–1205.
27. Devito, C.; Zuber, B.; Schroder, U.; Benthin, R.; Okuda, K.; Broliden, K.; Wahren, B.; Hinkula, J. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. *J. Immunol.* **2004**, *173*, 7078–7089.

28. Hinkula, J.; Devito, C.; Zuber, B.; Benthin, R.; Ferreira, D.; Wahren, B.; Schroder, U. A novel DNA adjuvant, N3, enhances mucosal and systemic immune responses induced by HIV-1 DNA and peptide immunizations. *Vaccine* **2006**, *24*, 4494–4497.
29. Brave, A.; Boberg, A.; Gudmundsdotter, L.; Rollman, E.; Hallermalm, K.; Ljungberg, K.; Blomberg, P.; Stout, R.; Paulie, S.; Sandstrom, E.; *et al.* A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice. *Mol. Ther.* **2007**, *15*, 1724–1733.
30. Hallengard, D.; Haller, B.K.; Petersson, S.; Boberg, A.; Maltais, A.K.; Isagulians, M.; Wahren, B.; Brave, A. Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity. *Vaccine* **2011**, *29*, 839–848.
31. Hallengard, D.; Applequist, S.E.; Nystrom, S.; Maltais, A.K.; Marovich, M.; Moss, B.; Earl, P.; Nihlmark, K.; Wahren, B.; Brave, A. Immunization with multiple vaccine modalities induce strong HIV-specific cellular and humoral immune responses. *Viral Immunol.* **2012**, *25*, 423–432.
32. Lisziewicz, J.; Trocio, J.; Whitman, L.; Varga, G.; Xu, J.; Bakare, N.; Erbacher, P.; Fox, C.; Woodward, R.; Markham, P.; *et al.* DermaVir: A novel topical vaccine for HIV/AIDS. *J. Investig. Dermatol.* **2005**, *124*, 160–169.
33. Ljungberg, K.; Rollman, E.; Eriksson, L.; Hinkula, J.; Wahren, B. Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. *Virology* **2002**, *302*, 44–57.
34. Brave, A.; Ljungberg, K.; Boberg, A.; Rollman, E.; Engstrom, G.; Hinkula, J.; Wahren, B. Reduced cellular immune responses following immunization with a multi-gene HIV-1 vaccine. *Vaccine* **2006**, *24*, 4524–4526.
35. Lisziewicz, J.; Toke, E.R. Nanomedicine applications towards the cure of HIV. *Nanomedicine* **2013**, *9*, 28–38.
36. Toke, E.R.; Lorincz, O.; Somogyi, E.; Lisziewicz, J. Rational development of a stable liquid formulation for nanomedicine products. *Int. J. Pharm.* **2010**, *392*, 261–267.
37. Lisziewicz, J.; Trocio, J.; Xu, J.; Whitman, L.; Ryder, A.; Bakare, N.; Lewis, M.G.; Wagner, W.; Pistorio, A.; Arya, S.; *et al.* Control of viral rebound through therapeutic immunization with DermaVir. *AIDS* **2005**, *19*, 35–43.
38. Pensiero, S.; Romiti, M.L.; Palma, P.; Castelli-Gattinara, G.; Bernardi, S.; Freda, E.; Rossi, P.; Cancrini, C. Switching from protease inhibitor-based-HAART to a protease inhibitor-sparing regimen is associated with improved specific HIV-immune responses in HIV-infected children. *AIDS* **2006**, *20*, 1893–1896.
39. Sandstrom, E.; Nilsson, C.; Hejdeman, B.; Brave, A.; Bratt, G.; Robb, M.; Cox, J.; Vancott, T.; Marovich, M.; Stout, R.; *et al.* Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. *J. Infect. Dis.* **2008**, *198*, 1482–1490.
40. Papagno, L.; Alter, G.; Assoumou, L.; Murphy, R.L.; Garcia, F.; Clotet, B.; Larsen, M.; Braibant, M.; Marcelin, A.G.; Costagliola, D.; *et al.* Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. *AIDS* **2011**, *25*, 27–36.

41. Nilsson, C.; Godoy-Ramirez, K.; Hejdeman, B.; Brave, A.; Gudmundsdotter, L.; Hallengard, D.; Currier, J.R.; Wiczorek, L.; Hasselrot, K.; Earl, P.L.; *et al.* Broad and potent cellular and humoral immune responses after a second late HIV-Modified vaccinia virus Ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees. *AIDS Res. Hum. Retrovir.* **2013**, *30*, 299–311.
42. Nowroozalizadeh, S.; Gudmundsdotter, L.; Hejdeman, B.; Andersson, L.; Esbjornsson, J.; Medstrand, P.; Sandstrom, E.; Gaines, H.; Wahren, B.; Jansson, M. Short-term HIV-1 treatment interruption is associated with dysregulated TLR-stimuli responsiveness. *Hum. Vaccines Immunother.* **2013**, *9*, 2103–2110.
43. Rolland, M.; Tovanabutra, S.; deCamp, A.C.; Frahm, N.; Gilbert, P.B.; Sanders-Buell, E.; Heath, L.; Magaret, C.A.; Bose, M.; Bradfield, A.; *et al.* Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. *Nat. Med.* **2011**, *17*, 366–371.
44. Prendergast, A.; Goodliffe, H.; Clapson, M.; Cross, R.; Tudor-Williams, G.; Riddell, A.; Daniels, J.; Williams, A.; Goulder, P. Gag-specific CD4+ T-cell responses are associated with virological control of paediatric HIV-1 infection. *AIDS* **2011**, *25*, 1329–1331.
45. Riou, C.; Ganusov, V.V.; Champion, S.; Mlotshwa, M.; Liu, M.K.; Whale, V.E.; Goonetilleke, N.; Borrow, P.; Ferrari, G.; Betts, M.R.; *et al.* Distinct kinetics of Gag-specific CD4+ and CD8+ T cell responses during acute HIV-1 infection. *J. Immunol.* **2012**, *188*, 2198–2206.
46. Ferrando-Martinez, S.; Casazza, J.P.; Leal, M.; Machmach, K.; Munoz-Fernandez, M.A.; Viciano, P.; Koup, R.A.; Ruiz-Mateos, E. Differential Gag-specific polyfunctional T cell maturation patterns in HIV-1 elite controllers. *J. Virol.* **2012**, *86*, 3667–3674.
47. SenGupta, D.; Tandon, R.; Vieira, R.G.; Ndhlovu, L.C.; Lown-Hecht, R.; Ormsby, C.E.; Loh, L.; Jones, R.B.; Garrison, K.E.; Martin, J.N.; *et al.* Strong human endogenous retrovirus-specific T cell responses are associated with control of HIV-1 in chronic infection. *J. Virol.* **2011**, *85*, 6977–6985.
48. Jones, R.B.; Garrison, K.E.; Mujib, S.; Mihajlovic, V.; Aidarus, N.; Hunter, D.V.; Martin, E.; John, V.M.; Zhan, W.; Faruk, N.F.; *et al.* HERV-K-specific T cells eliminate diverse HIV-1/2 and SIV primary isolates. *J. Clin. Investig.* **2012**, *122*, 4473–4489.
49. Tandon, R.; SenGupta, D.; Ndhlovu, L.C.; Vieira, R.G.; Jones, R.B.; York, V.A.; Vieira, V.A.; Sharp, E.R.; Wiznia, A.A.; Ostrowski, M.A.; *et al.* Identification of human endogenous retrovirus-specific T cell responses in vertically HIV-1-infected subjects. *J. Virol.* **2011**, *85*, 11526–11531.
50. Bakari, M.; Aboud, S.; Nilsson, C.; Francis, J.; Buma, D.; Moshiro, C.; Aris, E.A.; Lyamuya, E.F.; Janabi, M.; Godoy-Ramirez, K.; *et al.* Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. *Vaccine* **2011**, *29*, 8417–8428.
51. Weinberger, B.; Herndler-Brandstetter, D.; Schwanninger, A.; Weiskopf, D.; Grubeck-Loebenstern, B. Biology of immune responses to vaccines in elderly persons. *Clin. Infect. Dis.* **2008**, *46*, 1078–1084.
52. Deeks, S.G.; Verdin, E.; McCune, J.M. Immunosenescence and HIV. *Curr. Opin. Immunol.* **2012**, *24*, 501–506.
53. Palma, P.; Rinaldi, S.; Cotugno, N.; Santilli, V.; Pahwa, S.; Rossi, P.; Cagigi, A. Premature B-cell senescence as a consequence of chronic immune activation: Implications for vaccination of immune compromised individuals. *Hum. Vaccines Immunother.* **2014**, *10*, PMID: 24759062.

54. Cagigi, A.; Rinaldi, S.; di Martino, A.; Manno, E.C.; Zangari, P.; Aquilani, A.; Cotugno, N.; Nicolosi, L.; Villani, A.; Bernardi, S.; *et al.* Premature immune senescence during HIV-1 vertical infection relates with response to influenza vaccination. *J. Allergy Clin. Immunol.* **2014**, *133*, 592–594.
55. Hultstrom, A.L.; Hejdeman, B.; Leandersson, A.C.; Bratt, G.; Carbone, E.; Wahren, B. Human natural killer cells in asymptomatic human immunodeficiency virus-1 infection. *Intervirology* **2000**, *43*, 294–301.
56. Rydstrom, L.L.; Ygge, B.M.; Tingberg, B.; Naver, L.; Eriksson, L.E. Experiences of young adults growing up with innate or early acquired HIV infection—A qualitative study. *J. Adv. Nurs.* **2013**, *69*, 1357–1365.

## Appendix

**Figure A1.** Schedule of 12 adult vaccinees. CD4<sup>+</sup> T-cells (bullets) and HIV-1 viral load (triangles) during vaccination (arrows) and repeated structured therapy interruption (STI) (white fields). All patients finally resumed antiretroviral therapy (shaded areas).

